Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas' and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
解锁市场时间线与信号动态
该公司进入各个市场的顺序 — 从最早到最新
Royalty Pharma任命孙鍶铭为亚洲区主管
Royalty Pharma任命孙锶铭为亚洲区主管
注册以查看完整信号动态
Royalty Pharma 的国际扩张与竞争对手的对比情况
Royalty Pharma你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Royalty Pharma你 | 0 | 0 | 0% | 0 | 11 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
Royalty Pharma任命孙健为亚洲区高级副总裁兼主管，自2026年5月起生效，以扩展其全球平台。
Royalty Pharma任命孙锶铭为高级副总裁兼亚洲区主管，自2026年5月起生效，将常驻香港领导公司在亚洲的特许权业务。
Royalty Pharma任命孙鍶铭为高级副总裁兼亚洲区主管，自2026年5月起生效，将常驻香港领导亚洲特许权业务。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Royalty Pharma 的业务、市场和增长信号的快速解答。
